WO2008131469A3 - Procédé de production de 2,4'-diméthyl-3-pipéridino-propiophénone (tolpérisone) de haute pureté, compositions pharmaceutiques renfermant ce composé, et formulations de principe actif renfermant de la tolpérisone - Google Patents

Procédé de production de 2,4'-diméthyl-3-pipéridino-propiophénone (tolpérisone) de haute pureté, compositions pharmaceutiques renfermant ce composé, et formulations de principe actif renfermant de la tolpérisone Download PDF

Info

Publication number
WO2008131469A3
WO2008131469A3 PCT/AT2008/000149 AT2008000149W WO2008131469A3 WO 2008131469 A3 WO2008131469 A3 WO 2008131469A3 AT 2008000149 W AT2008000149 W AT 2008000149W WO 2008131469 A3 WO2008131469 A3 WO 2008131469A3
Authority
WO
WIPO (PCT)
Prior art keywords
tolperisone
ppm
propiophenone
piperidino
dimethyl
Prior art date
Application number
PCT/AT2008/000149
Other languages
German (de)
English (en)
Other versions
WO2008131469A2 (fr
Inventor
Stefan Welzig
Jan Rothenburger
Beate Kaelz
Jozsef Gungl
Klaus Gerdes
Federico Gaeta
Original Assignee
Sanochemia Pharmazeutika Ag
Stefan Welzig
Jan Rothenburger
Beate Kaelz
Jozsef Gungl
Klaus Gerdes
Federico Gaeta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutika Ag, Stefan Welzig, Jan Rothenburger, Beate Kaelz, Jozsef Gungl, Klaus Gerdes, Federico Gaeta filed Critical Sanochemia Pharmazeutika Ag
Priority to EP08733252.4A priority Critical patent/EP2150540B1/fr
Priority to CN200880019279A priority patent/CN101754958A/zh
Priority to MX2009011543A priority patent/MX2009011543A/es
Priority to JP2010504375A priority patent/JP5377473B2/ja
Priority to ES08733252.4T priority patent/ES2587369T3/es
Priority to US12/597,722 priority patent/US8372979B2/en
Priority to CA002683634A priority patent/CA2683634A1/fr
Publication of WO2008131469A2 publication Critical patent/WO2008131469A2/fr
Publication of WO2008131469A3 publication Critical patent/WO2008131469A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

L'invention concerne un procédé de production de 2,4'-diméthyl-3-pipéridino-propiophénone (tolpérisone), et de ses sels, chlorhydrates et hydrates pharmaceutiquement acceptables, procédé permettant de réduire sensiblement, par rapport aux procédés connus, la fraction de produit secondaire indésirable, 2-méthyl-1-(4-méthylphényl)-propénone (4-MMPPO). L'invention concerne en outre des formulations de principe actif contenant de la tolpérisone, qui sont appropriées entre autres pour la production de préparations de combinaisons pour la thérapie et le traitement de patients atteints de la maladie d'Alzheimer. L'invention concerne en outre des formulations topiques, des formulations à libération contrôlée (CR), et des systèmes transdermiques, thérapeutiques, tels que des timbres à substances actives qui contiennent moins de 50 ppm, de préférence, moins de 10 ppm, voire, moins de 7 ppm, ou mieux, moins de 3 ppm ou 0 ppm ( c'est-à-dire inférieur à la limite détectable) de produit secondaire indésirable, 2-méthyl-1-(4-méthylphényl)-propénone (4-MMPPO) pour 100 % en poids de principe actif.
PCT/AT2008/000149 2007-04-26 2008-04-24 Procédé de production de 2,4'-diméthyl-3-pipéridino-propiophénone (tolpérisone) de haute pureté, compositions pharmaceutiques renfermant ce composé, et formulations de principe actif renfermant de la tolpérisone WO2008131469A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP08733252.4A EP2150540B1 (fr) 2007-04-26 2008-04-24 Procédé de production de 2,4'-diméthyl-3-pipéridino-propiophénone (tolpérisone) de haute pureté, compositions pharmaceutiques renfermant ce composé, et formulations de principe actif renfermant de la tolpérisone
CN200880019279A CN101754958A (zh) 2007-04-26 2008-04-24 制备高纯度的2,4′-二甲基-3-哌啶-苯丙酮(托哌酮)的方法,包含其的药物组合物以及包含托哌酮的活性物质配制剂
MX2009011543A MX2009011543A (es) 2007-04-26 2008-04-24 Metodo para la produccion de la 2,4'-dimetil-3-piperidino-propiofe nona (tolperisona), altamente pura, composiciones farmaceuticas que contienen la misma al igual que formulaciones de ingrediente activo que contienen la tolperisona.
JP2010504375A JP5377473B2 (ja) 2007-04-26 2008-04-24 高純度の２，４’−ジメチル−３−ピペリジノ−プロピオフェノン（トルペリゾン）、これを含む医薬品組成物の製造法、並びにトルペリゾン含有活性物質組成物
ES08733252.4T ES2587369T3 (es) 2007-04-26 2008-04-24 Procedimiento para la preparación de 2,4'-dimetil-3-piperidinopropiofenona (tolperisona) de alta pureza, composiciones farmacéuticas que contienen esta, así como formulaciones de principios activos que contienen tolperisona
US12/597,722 US8372979B2 (en) 2007-04-26 2008-04-24 Process for the production of high-purity 2,4′-dimethyl-3-piperidino-propiophenone (tolperisone), pharmaceutical compositions that contain the latter, as well as active ingredient formulations that contain tolperisone
CA002683634A CA2683634A1 (fr) 2007-04-26 2008-04-24 Procede de production de 2,4'-dimethyl-3-piperidino-propiophenone (tolperisone) de haute purete, compositions pharmaceutiques renfermant ce compose, et formulations de principe actif renfermant de la tolperisone

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
ATA658/2007 2007-04-26
AT6582007 2007-04-26
AT0195307A AT505225A1 (de) 2007-04-26 2007-11-29 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
ATA1953/2007 2007-11-29
US2728708P 2008-02-08 2008-02-08
US61/027,287 2008-02-08

Publications (2)

Publication Number Publication Date
WO2008131469A2 WO2008131469A2 (fr) 2008-11-06
WO2008131469A3 true WO2008131469A3 (fr) 2009-04-23

Family

ID=39944530

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/AT2008/000149 WO2008131469A2 (fr) 2007-04-26 2008-04-24 Procédé de production de 2,4'-diméthyl-3-pipéridino-propiophénone (tolpérisone) de haute pureté, compositions pharmaceutiques renfermant ce composé, et formulations de principe actif renfermant de la tolpérisone
PCT/US2008/005281 WO2008133937A2 (fr) 2007-04-26 2008-04-24 Compositions de tolperisone

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2008/005281 WO2008133937A2 (fr) 2007-04-26 2008-04-24 Compositions de tolperisone

Country Status (13)

Country Link
US (7) US8372979B2 (fr)
EP (2) EP2146976A2 (fr)
JP (2) JP5377473B2 (fr)
KR (2) KR20100031095A (fr)
CN (2) CN101679329A (fr)
AT (1) AT505225A1 (fr)
BR (1) BRPI0810670A2 (fr)
CA (2) CA2683634A1 (fr)
ES (1) ES2587369T3 (fr)
HU (1) HUE028942T2 (fr)
MX (2) MX2009011543A (fr)
RU (1) RU2009143670A (fr)
WO (2) WO2008131469A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT505225A1 (de) 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
HUP0700828A2 (en) * 2007-12-20 2010-01-28 Richter Gedeon Nyrt Transdermal pharmaceutical compositions containing tolperisone alone and in combination
US20100249423A1 (en) 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet
KR101156054B1 (ko) * 2011-09-05 2012-06-20 주식회사 네비팜 안정한 에페리손 함유 서방성 의약조성물
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
CN107868065B (zh) * 2017-10-19 2021-05-18 湖北美林药业有限公司 一种盐酸托哌酮化合物及其制备方法
EP3709989A4 (fr) * 2017-11-17 2021-09-08 Neurana Pharmaceuticals, Inc. Méthodes d'administration de tolpérisone
CN110412141A (zh) * 2018-04-28 2019-11-05 人福普克药业（武汉）有限公司 一种测定盐酸金刚烷胺软胶囊残留溶剂异丙醇的方法
TR201820976A2 (tr) * 2018-12-28 2020-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇ngoli̇mod ve bi̇r spazmoli̇ti̇k i̇çeren farmasöti̇k kombi̇nasyonlar
CN110845443B (zh) * 2019-12-11 2023-09-05 嘉实（湖南）医药科技有限公司 一种制备高纯度盐酸托哌酮的方法
WO2021146425A1 (fr) * 2020-01-14 2021-07-22 Neurana Pharmaceuticals, Inc. Méthodes de traitement de spasmes musculaires aigus
CN116253699A (zh) * 2021-12-09 2023-06-13 广州白云山汉方现代药业有限公司 一种盐酸托哌酮新晶型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050648A1 (fr) * 2002-12-05 2004-06-17 Sanochemia Pharmazeutika Ag Procede de production de sels de tolperisone
WO2005084676A1 (fr) * 2004-03-05 2005-09-15 Sanochemia Pharmazeutika Ag Preparation pharmaceutique a liberation controlee de l'agent actif, contenant de la tolperisone, destinee a une administration orale

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5191315A (ja) * 1975-02-06 1976-08-10 Anteinaensantoruperizonshirotsupunoseizoho
JPS5340779A (en) 1976-09-21 1978-04-13 Nippon Kayaku Co Ltd Optically active tolpertisone, their preparation and pharmaceuticals containting the same
JPS607627B2 (ja) 1977-08-02 1985-02-26 旭化成株式会社 ピペリジン誘導体の製造方法
JPS5430178A (en) 1977-08-05 1979-03-06 Asahi Chem Ind Co Ltd Preparation of propiophenone derivative
JPS5432480A (en) 1977-08-19 1979-03-09 Asahi Chem Ind Co Ltd Novel preparation of piperidine derivatives
JPS5436274A (en) 1977-08-24 1979-03-16 Asahi Chem Ind Co Ltd Preparation of propiophenone derivative
JPS6143108A (ja) 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
PL149493B1 (en) 1985-04-12 1990-02-28 Method of obtaining a tablet capable to buoy over surface of gastric juice
JPH0720866B2 (ja) 1987-05-15 1995-03-08 三生製薬株式会社 エペリゾン又はトルペリゾン或いはそれらの塩類含有経皮適用製剤
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
DE3803482A1 (de) 1988-02-05 1989-08-17 Lohmann Therapie Syst Lts Schwimmfaehiges orales therapeutisches system
JPH045283A (ja) 1990-04-24 1992-01-09 Toyo Pharma- Kk アミノプロピオフェノン誘導体又はその塩の製造方法
WO1995005809A1 (fr) 1993-08-20 1995-03-02 Nippon Shinyaku Co., Ltd. Preparation restant dans l'estomac, forme moulee gonflee, et procede de preparation
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
FR2784583B1 (fr) 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
AT409083B (de) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
AU2003272069A1 (en) 2002-06-26 2004-01-19 Cadila Healthcare Limited Novel floating dosage form
KR100511492B1 (ko) 2002-10-11 2005-08-31 주식회사 태평양 에페리손, 톨페리손 또는 그것들의 염을 포함하는경피흡수제제
US20060004050A1 (en) 2004-07-02 2006-01-05 Speicher Brian T Compositions and methods for the prevention or treatment of pain and other nervous system disorders
CA2598204C (fr) * 2004-11-09 2015-01-13 Board Of Regents, The University Of Texas System Composition de petites particules medicamenteuses chauffee et stabilisee
DE102005014080B4 (de) 2005-03-21 2007-11-22 Birds Pharma Gmbh Berolina Innovative Research & Development Services Additionssalze des Tolperison, Verfahren zu deren Herstellung, Verwendung derselben und diese enthaltende Arzneimittel
TW200732292A (en) * 2006-02-01 2007-09-01 Shell Int Research A method of treating an aldehyde mixture, use of the treated aldehyde, and an alcohol
AT505225A1 (de) 2007-04-26 2008-11-15 Sanochemia Pharmazeutika Ag 0erfahren zur herstellung von hoch reinem 2,4'-dimethyl-3-piperidino-propiophenon (tolperison), dieses enthaltende pharmazeutische zusammensetzungen, sowie tolperison enthaltende wirkstoffformulierungen
HUP0700485A3 (en) 2007-07-23 2010-01-28 Richter Gedeon Nyrt Pharmaceutical composition with controlled release containing tolperisone
US20100249423A1 (en) 2009-03-09 2010-09-30 Sanochemia Pharmazeutika Ag Tolperisone controlled release tablet

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050648A1 (fr) * 2002-12-05 2004-06-17 Sanochemia Pharmazeutika Ag Procede de production de sels de tolperisone
WO2005084676A1 (fr) * 2004-03-05 2005-09-15 Sanochemia Pharmazeutika Ag Preparation pharmaceutique a liberation controlee de l'agent actif, contenant de la tolperisone, destinee a une administration orale

Also Published As

Publication number Publication date
US20100150995A1 (en) 2010-06-17
CN101679329A (zh) 2010-03-24
WO2008133937A3 (fr) 2008-12-24
EP2146976A2 (fr) 2010-01-27
US9315480B2 (en) 2016-04-19
MX2009011544A (es) 2010-03-31
CN101754958A (zh) 2010-06-23
MX2009011543A (es) 2009-12-08
KR20100031095A (ko) 2010-03-19
US20160220549A1 (en) 2016-08-04
KR20100016123A (ko) 2010-02-12
JP2010524977A (ja) 2010-07-22
CA2685268C (fr) 2016-08-02
CA2685268A1 (fr) 2008-11-06
EP2150540B1 (fr) 2016-06-01
WO2008131469A2 (fr) 2008-11-06
ES2587369T3 (es) 2016-10-24
AT505225A1 (de) 2008-11-15
JP2010525060A (ja) 2010-07-22
US9675598B2 (en) 2017-06-13
US20100324090A1 (en) 2010-12-23
US20160367540A1 (en) 2016-12-22
JP5377473B2 (ja) 2013-12-25
US9662317B2 (en) 2017-05-30
US20180344717A1 (en) 2018-12-06
EP2150540A2 (fr) 2010-02-10
WO2008133937A2 (fr) 2008-11-06
US20170239228A1 (en) 2017-08-24
CA2683634A1 (fr) 2008-11-06
RU2009143670A (ru) 2011-06-10
BRPI0810670A2 (pt) 2017-05-09
US20090253743A1 (en) 2009-10-08
HUE028942T2 (hu) 2017-01-30
US8372979B2 (en) 2013-02-12

Similar Documents

Publication Publication Date Title
WO2008131469A3 (fr) Procédé de production de 2,4'-diméthyl-3-pipéridino-propiophénone (tolpérisone) de haute pureté, compositions pharmaceutiques renfermant ce composé, et formulations de principe actif renfermant de la tolpérisone
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
WO2005075425A3 (fr) Derives de bisaryluree
WO2009066152A3 (fr) Inhibiteurs de ssao/vap-1 de type haloallylamines et leurs utilisations
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2010136474A3 (fr) Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine
NO20090328L (no) Nye forbindelser 385
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
WO2009010416A3 (fr) Inhibiteurs de 11b-hydroxystéroïde déshydrogenase
WO2004052847A3 (fr) Modulateurs tricycliques du recepteur nucleaire des hormones steroidiennes
WO2007143607A3 (fr) Procédé de traitement de la vaginite atrophique
UA86977C2 (ru) Производные гидантоина для лечения обструктивных болезней дыхательных путей
MX2012007326A (es) Polivinilpirrolidona para la estabilizacion de una dispersion solida de forma no cristalina de rotigotina.
ZA201002596B (en) 1,2,3-triazole derivatives for use as stearoyl-coa destaurase inhibitors
WO2009025785A3 (fr) Ligands de récepteur cb2 pour le traitement de la douleur
EA201071094A1 (ru) Тризамещенные 1,2,4-триазолы в качестве модуляторов никотиновых ацетилхолиновых рецепторов
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
TW200626158A (en) Naphthaline derivatives
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
WO2005037798A3 (fr) Nouveaux composés
MX2009010559A (es) Derivados de heteroarilo.
WO2010098600A3 (fr) Dérivés d'azole substitués, composition pharmaceutique contenant les dérivés et procédé de traitement de la maladie de parkinson à l'aide de ceux-ci
MX2010007672A (es) Composicion estabilizada de liberacion sostenida de clorhidrato de bupropion y proceso para su preparacion.
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880019279.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08733252

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2683634

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010504375

Country of ref document: JP

Ref document number: MX/A/2009/011543

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20097023635

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008733252

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12597722

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 12597722

Country of ref document: US